Navigation Links
MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Date:1/7/2008

- Expands Staff to Continue Record of Investment Success -

GAITHERSBURG, Md., Jan. 7 /PRNewswire/ -- MedImmune, the operationally independent worldwide biologics unit of AstraZeneca plc (LSE: AZN.L, NYSE: AZN), today announced that its highly successful venture capital fund, MedImmune Ventures, will broaden its focus to include areas of strategic interest to both organizations by adding the therapeutic areas of cardiovascular and metabolic disease, pain and central nervous system disorders and gastrointestinal disease. Traditionally, MedImmune Ventures has focused its efforts on the areas of infectious disease, oncology and inflammatory disease. Since its inception in 2002, MedImmune Ventures has invested in 22 companies.

"We look forward to making meaningful investments in these additional therapeutic areas," said Edward T. Mathers, executive vice president, corporate development and venture, MedImmune. "Now that we are more fully aligned with AstraZeneca's core areas of interest, we are able to help both MedImmune and AstraZeneca to stay at the forefront of novel science with a direct window to the most innovative start-ups in the biotechnology industry."

Mr. Mathers and MedImmune President & CEO David M. Mott currently lead MedImmune Ventures. To accommodate the broader disease area focus, MedImmune Ventures has added Maggie Flanagan LeFlore, Ph.D. and Eva M. Jack as managing directors to its team of experts that oversee the assessment of all new investment opportunities. Previously, Dr. LeFlore was on assignment from AstraZeneca to the healthcare and life science venture investment team at Advent International, and Ms. Jack was director, business development at MedImmune. Also, Joseph L. Amprey, M.D., Ph.D. was promoted to managing director of MedImmune Ventures following the June 2007 retirement of its president, Wayne T. Hockmeyer, Ph.D. Franklin H. Top, M.D., who has been with MedImmune since 1988 and is the company's former m
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. MedImmune Announces Seven Key Promotions and New Hires
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
10. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
11. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2
... N.C. , May 13 Chimerix, Inc., ... the commencement of a first-in-human study of CMX157, a ... in vitro activity against both tenofovir-sensitive and tenofovir-resistant ... increase efficacy and decrease toxicity as compared to tenofovir, ...
... LA JOLLA, Calif. , May 13 Transdel ... focused on developing topically administered products using its proprietary transdermal ... March 31, 2010 .  The Company also highlighted recent ... , ...
... , DUBLIN and PHILADELPHIA , ... ), the global specialty biopharmaceutical company,announces that its subsidiary Shire LLC has ... Delaware against Actavis Elizabeth LLC and,Actavis Inc. (collectively "Actavis") for the ... and 6,811,794,(the ,794 patent). , , ...
Cached Biology Technology:Chimerix Initiates Phase 1 Study of CMX157 2Chimerix Initiates Phase 1 Study of CMX157 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 2Transdel Pharmaceuticals Reports First Quarter 2010 Results 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 4Transdel Pharmaceuticals Reports First Quarter 2010 Results 5INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 2INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 3
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
(Date:7/10/2014)... 2014 Amidst the astounding complexity of the billions ... the brain, how do nerve cells decide how far ... do they coordinate these events within the developing brain? ... campus of The Scripps Research Institute (TSRI) have shed ... particular protein plays a far more sophisticated role in ...
(Date:7/10/2014)... Ore. Nuclear engineers at Oregon State University have ... device that should help people all over the world ... intensity, and whether or not it poses a health ... to public demand following the nuclear incident in Fukushima, ... what level of radiation they were being exposed to ...
Breaking Biology News(10 mins):Marshall University to partner with international company in drug development venture 2Scripps Florida scientists shed new light on nerve cell growth 2Sophisticated radiation detector designed for broad public use 2Sophisticated radiation detector designed for broad public use 3
... research into cheetah cub survival has refuted the theory that ... cannot coexist in conservation areas. The study, published in the ... Kgalagadi Transfrontier Park were seven times more likely to survive ... found to be the cubs, main predatory threat. Previously, ...
... MA -- Researchers at MIT and Brigham and Women,s ... of intestinal stem cells, then stimulate them to develop ... intestinal cells. Using these cells, scientists could develop and ... colitis. The small intestine, like most other body ...
... approach to mapping how proteins interact with each other, ... aid in the design of new drugs for diseases ... artificial amino acids, the Salk scientists determine the detailed ... the molecule that turns it on. The switch--corticotrophin releasing ...
Cached Biology News:Researchers unlock a new means of growing intestinal stem cells 2Researchers unlock a new means of growing intestinal stem cells 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: